A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata

A 25-year-old male patient with extensive and resistant Alopecia Areata (AA) showed significant improvement after being treated with Tofacitinib, a Janus kinase (JAK) inhibitor, for 6 months. The patient had previously shown no signs of improvement after 5-6 months of treatment with minoxidil lotion 5% and betamethasone 1 mg. After starting Tofacitinib (5 mg) twice daily, hair regrowth was evident by the 2nd month and near-total recovery was achieved by the 6th month. The dose was then adjusted to 5 mg once daily for maintenance. Despite potential side effects such as dyslipidemia, anemia, thrombocytopenia, and increased susceptibility to infections, Tofacitinib was well tolerated in this case. This case report contributes to the limited data on the efficacy of Tofacitinib within the Indian population and encourages further research to ascertain its broader implications.